Your Article Summary
See Latest ArticlesSorensen FB et al. - The studied series of patients documented already prior to the chemotherapy era, a rather excellent survival and estimates of angiogenesis, proliferation, p53, and Pgp expressions, did not demonstrate sufficient power to serve as predictors of treatment response or survival.
Related Articles
The role of interferons in the treatment of osteosarcoma
Pediatric Blood & Cancer, 11/12/09
Relevance Score: 88%
Reconstruction Using a Frozen Bone Method for Osteosarcoma of the Talus. A Case Report and Review of the Literature
Anticancer Research, 11/11/09
Relevance Score: 88%
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
British Journal of Cancer, 11/06/09
Relevance Score: 88%
Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience
Acta Oncologica, 10/26/09
Relevance Score: 88%
Tumoral Calcinosis Mimicking Recurrent Osteosarcoma
Radiology Case Reports, 10/23/09
Relevance Score: 88%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Clinical Cancer Research, 12/11/09
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Clinical Cancer Research, 12/11/09
Platelets release novel thiol isomerase enzymes which are recruited to the cell surface following activation
British Journal of Haematology, 12/11/09
Today in Soft Tissue/Sarcoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases
Annals of Diagnostic Pathology, 12/11/09
Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype
British Journal of Cancer, 12/11/09
HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies
Expert Opinion in Pharmacotherapy, 12/11/09